Telix Pharmaceuticals Revenue

In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.

Revenue (ttm)

$803.79M

Revenue Growth

+55.61%

P/S Ratio

4.99

Revenue / Employee

$678,880

Employees

1,184

Market Cap

4.01B

Revenue Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	803.79M	287.24M	55.61%
Dec 31, 2024	516.55M	183.57M	55.13%
Dec 31, 2023	332.98M	224.03M	205.64%
Dec 31, 2022	108.95M	103.42M	1,873.24%
Dec 31, 2021	5.52M	1.51M	37.53%
Dec 31, 2020	4.01M	1.57M	64.21%
Dec 31, 2019	2.44M	2.31M	1,680.88%
Dec 31, 2018	137.28K	-	-
Dec 31, 2017	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company Name	Revenue
Legend Biotech	1.27B
IDEAYA Biosciences	234.13M
Arcus Biosciences	117.00M
Tango Therapeutics	53.81M
Relay Therapeutics	10.35M
Denali Therapeutics	3.60M

Revenue Rankings

TLX News

8 days ago - Telix to Host R&D Day in New York City on September 22, 2026 - GlobeNewsWire
23 days ago - TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - GlobeNewsWire
23 days ago - Telix Pharma Q2 Revenue Rises 21%; Doses First Patient In Phase 3 LUTEON Trial; Shares Jump - Nasdaq
24 days ago - Telix Pharmaceuticals (TLX) Reports Strong Q2 Revenue Growth and Upbeat FY 2026 Outlook - GuruFocus
24 days ago - Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business - Nasdaq
24 days ago - Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewsWire
24 days ago - Telix Pharmaceuticals Earnings release: Q2 2026 - Filings
24 days ago - Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - GlobeNewsWire

More News